{
  "id": "mhgap#risk_safety_cdd29475",
  "content": "carbamazepine in terms of adverse events (HR =\nonset epilepsy, although they may exacerbate other\n0.56; 95% CI: 0.44 to 0.73 for lamotrigine versus\nseizure types in these individuals. Gabapentin is not\ncarbamazepine, HR = 0.65; 95% CI: 0.47 to 0.90 for\nan appropriate medicine in generalized epilepsy\nlevetiracetam versus carbamazepine). Valproic acid\nand should only be considered in those with focal\nalso has an advantage over carbamazepine in terms\nonset seizures.\nof adverse events (HR = 1.96; 95% CI: 1.13 to 3.39).\ny No systematic review of RCTs comparing these ASMs\ny Given the risks associated with sodium valproate if\nwith placebo was found. It is considered unethical to\nprescribed to women and girls who are able to have\nconduct RCTs comparing standard ASMs, especially\nchildren, lamotrigine or levetiracetam should be\nas monotherapy, with placebo in established\nused as first-line treatment in this population.\nepilepsy as epilepsy should be treated to decrease\ny For focal onset seizures there is high-certainty\nmorbidity and premature mortality.\nevidence to suggest that carbamazepine performs\ny Both levetiracetam and sodium valproate are\nbetter than gabapentin in terms of seizure\neffective against all types of seizures, and hence may",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety carbamazepine in terms of adverse events (HR =\nonset epilepsy, although they may exacerbate other\n0.56; 95% CI: 0.44 to 0.73 for lamotrigine versus\nseizure types in these individuals. Gabapentin is not\ncarbamazepine, HR = 0.65; 95% CI: 0.47 to 0.90 for\nan appropriate medicine in generalized epilepsy\nlevetiracetam versus carbamazepine). Valproic acid\nand should only be considered in those with focal\nalso has an advantage over carbamazepine in terms\nonset seizures.\nof adverse events (HR = 1.96; 95% CI: 1.13 to 3.39).\ny No systematic review of RCTs comparing these ASMs\ny Given the risks associated with sodium valproate if\nwith placebo was found. It is considered unethical to\nprescribed to women and girls who are able to have\nconduct RCTs comparing standard ASMs, especially\nchildren, lamotrigine or levetiracetam should be\nas monotherapy, with placebo in established\nused as first-line treatment in this population.\nepilepsy as epilepsy should be treated to decrease\ny For focal onset seizures there is high-certainty\nmorbidity and premature mortality.\nevidence to suggest that carbamazepine performs\ny Both levetiracetam and sodium valproate are\nbetter than gabapentin in terms of seizure\neffective against all types of seizures, and hence may Carbamazepine in terms of adverse events (hr =\nonset epilepsy, although they may exacerbate other\n0.56; 95% ci: 0.44 to 0.73 for lamotrigine versus\nseizure types in these individuals. gabapentin is not\ncarbamazepine, hr ..."
}